摘要
抑郁是阿尔兹海默症患者中一种常见的神经生理学表现。它可能包括每天的日常活动并导致认知的快速下降。有研发前景的生物标记物的鉴定可能因此及时激活和改善AD临床前和临床的治疗以及长期功能性障碍的结果。本文报道了AD患者相关的抑郁的生物标记物的研究,遗传结果表明AD相关的抑郁症作为一个相当复杂的多因素行为,多与环境和遗传有关。然而,一组特定的基因—脑源性神经营养因子(BDNF),特别是Val66Met多态性,可能在AD相关抑郁症中发挥关键作用。关于神经影像学标记物,最有前景的发现结合在与影响上调下调有关的皮质-皮质下网络。功能性影响研究显示主要在额叶和颞区的异常。此外,基于CSF的生物标记物被认为是一种有前景的标记物,它的诊断过程显示促成AD相关抑制的代谢途径异常。然而,还需要标准化方法学中的问题并需要更大的队列和前瞻性研究来重复现有的研究。
关键词: 阿尔兹海默症、抑郁症、生物标记物、阿尔兹海默症中的抑郁、神经生理学、遗传学、血清生物标志物、BDNF
Current Alzheimer Research
Title:Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review
Volume: 14 Issue: 4
关键词: 阿尔兹海默症、抑郁症、生物标记物、阿尔兹海默症中的抑郁、神经生理学、遗传学、血清生物标志物、BDNF
摘要: Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.
Export Options
About this article
Cite this article as:
Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160603011256
DOI https://dx.doi.org/10.2174/1567205013666160603011256 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α-Synuclein- and MPTP-Generated Rodent Models of Parkinsons Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach
CNS & Neurological Disorders - Drug Targets Radix Angelica Sinensis that Contains the Component Z-Ligustilide Promotes Adult Neurogenesis to Mediate Recovery from Cognitive Impairment
Current Neurovascular Research Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design 3D-QSAR and Molecular Docking Studies of Flavonoid Derivatives as Potent Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets NAP Protects against Tau Hyperphosphorylation Through GSK3
Current Pharmaceutical Design Integrated System Pharmacology and <i>In Silico</i> Analysis Elucidating Neuropharmacological Actions of <i>Withania somnifera</i> in the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Statistical Signal Processing in the Analysis, Characterization and Detection of Alzheimer's Disease)
Current Alzheimer Research Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Accurate and Unbiased Quantitation of Amyloid-β Fluorescence Images Using ImageSURF
Current Alzheimer Research Bioactivity Guided Isolation of Quercetin as Anxiolytic Compound from Elaeocarpus ganitrus Beads
The Natural Products Journal Preface
Current Psychopharmacology Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Experience and Perspectives of Caregivers of Spouse with Mild Cognitive Impairment
Current Alzheimer Research Insulin and the Future Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Bilateral Interrelationship of Diabetes and Periodontium
Current Diabetes Reviews Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Acetylcholinesterase-Amyloid-β-peptide Interaction: Effect of Congo Red and the Role of the Wnt Pathway
Current Alzheimer Research Curcumin Suppresses Tumor Growth and Angiogenesis in Human Glioma Cells Through Modulation of Vascular Endothelial Growth Factor/ Angiopoietin-2/Thrombospondin-1 Signaling
CNS & Neurological Disorders - Drug Targets The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review
Current Psychiatry Reviews